Simple biomarkers offer early warning of hidden heart risk in childhood cancer survivors

Data from the St. Jude lifetime cohort study (St. Jude LIFE) revealed that two common biomarkers of cardiac function and damage could better predict cardiomyopathy within five years than routine clinical evaluations in high-risk, asymptomatic childhood cancer survivors.

Lifestyle Interventions and Cognitive Decline in Alzheimer’s and Dementia

Cognitive decline in Alzheimer’s and other dementias may be delayed for some at-risk older adults, recent clinical trials have suggested. The ACHIEVE study, for example,

March 14, 2024

AstraZeneca expands stake in cell and gene therapy partner Cellectis

UK pharma giant AstraZeneca on Monday unveiled another $140 million equity investment in cell and gene therapy partner Cellectis. AstraZeneca now owns 44% of Cellectis’

May 7, 2024

Eganelisib by Infinity Pharmaceuticals for Metastatic Ovarian Cancer: Likelihood of Approval – Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

October 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.